India Tapentadol Market Size, Share, Industry, Forecast and outlook 2024-2031

India Tapentadol Market is segmented By Product Type (100 mg Tablets, 75 mg Tablets, 50 mg Tablets), By Application (Neuropathic Pain, Musculoskeletal Pain, Chronic Pain Treatment, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others),  – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The India Tapentadol Market reached US$ 28.24 million in 2023 and is expected to reach US$ 45.55 million by 2031, growing at a CAGR of 6.2% during the forecast period 2024-2031. 

Tapentadol is a dual-mode analgesic that performs the actions of being a norepinephrine reuptake inhibitor and a mu-opioid receptor antagonist. Its analgesic properties come into effect within a few minutes of oral administration. Tapentadol has been recognized as a step three analgesic on the World Health Organization (WHO) pain ladder. Tapentadol is utilized for the treatment of moderate to severe pain for chronic and acute musculoskeletal pain. In India, multiple brands of Tapentadol are available over the counter. 

There is an increase in tapentadol abuse and dependence in India, where users have improvised injections with 50 and 100 mg tablets. The tapentadol market growth is driven by the surge in the prevalence of chronic disorders, such as chronic musculoskeletal pain, which is a key factor fueling the demand for tapentadol across the globe. Tapentadol is further used for the treatment of moderate to severe acute pain. In addition, a rise in the number of patients who have painful diabetic peripheral neuropathy significantly contributes to the growth of the tapentadol market.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing prevalence of neuropathy

The rising prevalence of neuropathy propels the market growth. For instance, according to the National Institute of Health, about 2.4% of the population is affected by peripheral neuropathy. The prevalence increases to 8% in older populations. Diabetic peripheral neuropathy eventually affects nearly 50% of adults with diabetes during their lifetime and is associated with substantial morbidity including pain, foot ulcers, and lower limb amputation. 

The prevalence of peripheral neuropathy is estimated to be between 6% and 51% among adults with diabetes depending on age, duration of diabetes, glucose control, and type 1 versus type 2 diabetes. The clinical manifestations are variable, ranging from asymptomatic to painful neuropathic symptoms. Because of the risk of foot ulcer (25%) and amputation associated with diabetic peripheral neuropathy.

Restraints

Factors such as adverse effects and risks related to tapentadol are expected to hamper the market. Tapentadol causes side effects like nausea, allergic reactions, difficulty with breathing, heart arrhythmia, anxiety, and serotonin syndrome. This acts as a restraint to the tapentadol market.

Market Segment Analysis

The India tapentadol market is segmented based on product type, application, and distribution channel.

The segment neuropathic pain accounted for approximately 52.4% of the India tapentadol market share

The neuropathic pain segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market. 

Tapentadol is a strong analgesic with a unique dual mechanism of action that combines μ-opioid receptor agonism (MOR) and norepinephrine reuptake inhibition (NRI), and has been proposed to be the first representative of a new class of drugs, the MOR-NRI agents (µ-opioid receptor agonists and norepinephrine reuptake inhibitors). The MOR mechanism interrupts pre- and post-synaptic transmissions of ascending pain signals in the spinal cord and activates the descending inhibitory projections supraspinally, while NRI increases synaptic norepinephrine and enhances the descending inhibitory tone. Finally, tapentadol shows minimal serotoninergic activity, which is important in the prolonged management of patients.

For instance, according to the Indian Academy of Neurology, peripheral neuropathy (PN) is a common disorder and presents as a diagnostic and therapeutic challenge to physicians and neurologists. In epidemiological studies from India from various regions, the overall prevalence of PN varied from 5 to 2400 per 10,000 population in various community studies.

Market Segmentation

By Product Type

• 100 mg Tablets
• 75 mg Tablets
• 50 gm Tablets

By Application

• Neuropathic Pain
• Musculoskeletal Pain
• Chronic Pain Treatment
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Market Competitive Landscape

The major players in the India tapentadol market include MSN Laboratories Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Zuventus Healthcare Ltd., Lupin, Sun Pharmaceutical Industries Ltd., Ventus Pharmaceuticals Pvt. Ltd., Glenmark Pharmaceuticals Ltd., Zydus Group among others.

Why Purchase the Report?

• To visualize the India tapentadol market segmentation based on product type, application, and distribution channel as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of India tapentadol market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The India tapentadol market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies